Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lilly Receives U.S. FDA Approval for Taltz for the Treatment of Active Ankylosing Spondylitis

The FDA approved Eli Lilly and Co.’s Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis, also known as radiographic axial spondyloarthritis.

Read More »

With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos’ Filgotinib Inches Toward Approval

Gilead Sciences Inc. and its partner Galapagos NV announced results from the Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom